Abstract
Background: Breast cancer-related lymphedema (BCRL) is a prevalent long-term condition secondary to cancer treatment. BCRL impacts physical function, psychological health, and quality of life for patients who have survived breast cancer.Objectives: This study will assess the feasibility of a fully-powered randomized controlled trial investigating the effectiveness of low level laser therapy (LLLT), also known as photobiomodulation (PBM) therapy, as an adjunct treatment for managing BCRL.Methods: This study will be a pragmatic two-armed randomized controlled feasibility trial. Twenty female participants being treated for BCRL at the Dunedin Hospital, New Zealand, will be recruited over a 6-month window. Subject to informed consent, participants will be offered LLLT (PBM) in addition to their regular treatment for BCRL. Twelve treatments with laser therapy will continue for 6 weeks (twice weekly). Feasibility outcomes (recruitment rate, randomization rate, participant’s adherence to the LLLT (PBM) treatment protocol, and participant retention rates) will be collected during the recruitment and intervention period. Participant satisfaction will be collected on completion of treatment intervention. Safety outcomes of LLLT (PBM) will be collected at each treatment visit. Clinical outcome measures (limb circumference, participant’s perceived symptoms, psychological impacts, and activity disability) will be assessed at baseline, 6 and 12 weeks post-randomization.Conclusions: Results of this feasibility trial will inform the design and implementation of a future definitive randomized controlled trial, which will investigate the effectiveness of LLLT (PBM) for women with BCRL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.